- Email: [email protected]
Current advances in ACE Inhibition 3
Book reviews /ht.
disorders. Many of the initial papers are scientifically orientated. The chapters on the interaction between lipoproteins and endothelial cells and the one on triglycerides in high density lipoprotein metabolism were very informative. Giesels’ findings that lipoprotein (a) does not predict restenosis after percutaneous transluminal coronary angioplasty, were noted with interest. The paper on lipid lowering for the prevention of recurrent stenosis after coronary angioplasty was of potential importance, but the conclusions were far from clear. Drug therapy for hypertriglyceridemia is a contentious issue, however the chapter by Illingworth gives clear guidelines for the role of such drugs in the management of severe hypertriglyceridemia. A comprehensive insight is also given at the end of the book on the technique and complication of low density lipoprotein apheresis in homozygous familial hypercholesterolemia. In short the book provides fascinating reading for those with a particular interest in lipoprotein metabolism; there are also areas which are of relevance to the clinical cardiologist. Department of Cardiology Glenfield General Hospital Leicester, UK SSDI
Dr N. Shaukat
0167-5273(94)02144-g
Current Advances in ACE Inhibition 3 G.A. MacGregor, P.S. Sever (Editors) Churchill Livingstone, Edinburgh, UK, 1994; 254 pp.; qE60.00; ISBN 0-443-05141-O This book is the proceedings of the Third International Meeting on Angiotensive Converting Enzyme Inhibition which took place in Amsterdam in March 1993. The contents consist of 48 articles and papers covering a wide range of topics relevant to ACE inhibitor therapy ranging from molecular genetics to more familiar clini-
J. Cardiol. 47 (1994)
81
85-87
cal problems. The contents are simply divided into two parts. Part one consists of 20 invited papers on a range of interesting topics by authors who are prominent in their areas of interest. This section is likely to be of greater interest to the clinician since the articles cover the interaction of ACE inhibitors with the pathophysiology of cardiovascular disease, and the therapeutics of hypertension, cardiac failure and renal disease. Part two consists of 28 brief papers presented in the style of research communications on more specific topics of animal and laboratory research, though some areas of clinical interest are also covered. This is a well presented short book containing well written and admirably concise papers. The interested reader will find a wide range of up to date information and thought covering, in particular, ACE inhibitor therapy and the pathophysiology of hypertension and vascular disease. The content largely reflects the interests of the editors. The cardiological content was relatively modest. This perhaps does not adequately reflect the enormous clinical and research interests in the use of ACE inhibitors in the management of heart failure in recent years, and there was little on more recent topics such as the role of ACE inhibitors in left ventricular remodelling and after myocardial infarction. It was perhaps unfortunate that the timing of the conference just pre-dated the presentation or publication of a number of important studies on these topics, notably the Aire study, Isis-4 and Gissi-3. No doubt these areas will be covered more thoroughly in the next volume in this series. Directorate of Integrated Medicine Department of Cardiology Leicester General Hospital Leicester, UK SSDI 0167-5273(94)02145-Z
Dr AJl &riven
disorders. Many of the initial papers are scientifically orientated. The chapters on the interaction between lipoproteins and endothelial cells and the one on triglycerides in high density lipoprotein metabolism were very informative. Giesels’ findings that lipoprotein (a) does not predict restenosis after percutaneous transluminal coronary angioplasty, were noted with interest. The paper on lipid lowering for the prevention of recurrent stenosis after coronary angioplasty was of potential importance, but the conclusions were far from clear. Drug therapy for hypertriglyceridemia is a contentious issue, however the chapter by Illingworth gives clear guidelines for the role of such drugs in the management of severe hypertriglyceridemia. A comprehensive insight is also given at the end of the book on the technique and complication of low density lipoprotein apheresis in homozygous familial hypercholesterolemia. In short the book provides fascinating reading for those with a particular interest in lipoprotein metabolism; there are also areas which are of relevance to the clinical cardiologist. Department of Cardiology Glenfield General Hospital Leicester, UK SSDI
Dr N. Shaukat
0167-5273(94)02144-g
Current Advances in ACE Inhibition 3 G.A. MacGregor, P.S. Sever (Editors) Churchill Livingstone, Edinburgh, UK, 1994; 254 pp.; qE60.00; ISBN 0-443-05141-O This book is the proceedings of the Third International Meeting on Angiotensive Converting Enzyme Inhibition which took place in Amsterdam in March 1993. The contents consist of 48 articles and papers covering a wide range of topics relevant to ACE inhibitor therapy ranging from molecular genetics to more familiar clini-
J. Cardiol. 47 (1994)
81
85-87
cal problems. The contents are simply divided into two parts. Part one consists of 20 invited papers on a range of interesting topics by authors who are prominent in their areas of interest. This section is likely to be of greater interest to the clinician since the articles cover the interaction of ACE inhibitors with the pathophysiology of cardiovascular disease, and the therapeutics of hypertension, cardiac failure and renal disease. Part two consists of 28 brief papers presented in the style of research communications on more specific topics of animal and laboratory research, though some areas of clinical interest are also covered. This is a well presented short book containing well written and admirably concise papers. The interested reader will find a wide range of up to date information and thought covering, in particular, ACE inhibitor therapy and the pathophysiology of hypertension and vascular disease. The content largely reflects the interests of the editors. The cardiological content was relatively modest. This perhaps does not adequately reflect the enormous clinical and research interests in the use of ACE inhibitors in the management of heart failure in recent years, and there was little on more recent topics such as the role of ACE inhibitors in left ventricular remodelling and after myocardial infarction. It was perhaps unfortunate that the timing of the conference just pre-dated the presentation or publication of a number of important studies on these topics, notably the Aire study, Isis-4 and Gissi-3. No doubt these areas will be covered more thoroughly in the next volume in this series. Directorate of Integrated Medicine Department of Cardiology Leicester General Hospital Leicester, UK SSDI 0167-5273(94)02145-Z
Dr AJl &riven